Hormone therapy safe for women, study finds

Hormone therapy safe for women
The study showed treatment using a combination of hormones estradiol and drospirenone resulted in significant improvement in menopausal symptoms.

(Medical Xpress)—A new study has examined the cognitive effects of hormone therapy on memory, language and concentration in menopausal women.

A study, published in the Menopause journal, examined the effects of (HRT) E2D, which used a combination of hormones estradiol and drospirenone to treat women. Early postmenopausal women aged between 49 and 55 who had never used HRT were assessed over a six-month period.

The treatment resulted in significant improvement in menopausal symptoms including hot flushes, night sweats, and sexual function, and it lowered blood pressure and weight in comparison to those who were treated with an identical placebo.

The women also underwent cognitive assessment and were asked to perform during a brain-imaging (MRI) scan.

Estradiol, a form of oestrogen combined with drospirenone, a progestin, were found to have no effect on the of early postmenopausal women.

Professor Susan Davis, Director of the Women's Health Research Program in the Monash University School of Public Health and Preventive Medicine, said there had long been debate about the safety of hormone replacement therapies and the potential adverse effects on cognitive function in women.

"These findings are reassuring for women," Professor Davis said.

"We report, for the first time, that combined with estradiol has no overall effect on the cognitive performance of postmenopausal women examined over a 26-week period.

"Although hormone replacement therapy is no quick fix to the challenge of menopause, it does show that the E2D treatment can be useful in the overall management of menopause, and without adversely effecting cognitive ability."

Professor Davis said memory and mood complaints were frequent in women after menopause due to oestrogen deficiency, including a lack of clarity of thought and memory or word-finding difficulties.

add to favorites email to friend print save as pdf

Related Stories

Testosterone therapy improves memory in postmenopausal women

Jun 06, 2011

Post-menopausal women have better memory after daily treatment with a testosterone spray for six months, a new preliminary study finds. The results will be presented Saturday at The Endocrine Society's 93rd Annual Meeting ...

Recommended for you

Determine patient preferences by means of conjoint analysis

5 hours ago

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

User comments